Do thyroid antibodies and CTLA4 rs231775 indicate autoimmune thyroid disease susceptibility?

Autoimmune thyroid diseases (AITD) are characterized by a loss of immune tolerance to thyroid-specific antigens, driven by genetic susceptibility and characterized by detectable serum biomarkers.

Diagnostic biomarkers and clinical utility

• Serum antibodies: Thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TgAb) serve as highly sensitive and specific clinical markers of active thyroid autoimmunity.
• Clinical sensitivity: TPOAb is elevated in approximately 95% of patients with Hashimoto's thyroiditis and correlates with lymphocytic infiltration. Its presence doubles the annual risk of progression from subclinical to overt hypothyroidism.
• Complementary utility: TgAb provides critical diagnostic value, particularly in identifying autoimmune thyroiditis in the subset of patients who are TPOAb-negative.

Mechanistic explanations and genetic susceptibility

• Disrupted immune checkpoints: The CTLA4 rs231775 (+49 A/G) polymorphism impairs natural immune checkpoint regulation. This non-synonymous mutation causes a Thr17 to Ala17 substitution in the leader peptide, leading to inefficient endoplasmic reticulum glycosylation and trafficking.
• T-cell activation: This trafficking defect reduces functional CTLA-4 on the T-cell surface, preventing it from outcompeting CD28 costimulation. The resulting unrestrained T-cell activation drives chronic inflammation and follicular cell destruction via antibody-dependent cell-mediated cytotoxicity (ADCC).
• Clinical risk: The G allele is strongly linked to elevated AITD susceptibility, carrying an odds ratio (OR) of 1.5 to 1.6 for Graves' disease and an OR of approximately 1.3 for Hashimoto's thyroiditis.

Bottom line

• Elevated TPO and Tg antibodies provide definitive clinical evidence of active thyroid autoimmunity, while the CTLA4 rs231775 G allele represents a validated genetic risk factor that impairs immune checkpoint regulation, directly increasing susceptibility to autoimmune thyroid pathology.